Therapy-Driven Cell-State Plasticity inER-Positive/HER2-Negative Breast Cancer: Adaptive Persistence, Acquired Resistance, and Recurrence—A Structured Narrative Review
OncoTargets and Therapy · 2026-11 · Volume 19 · 1-28
DOI: 10.2147/ott.s661018 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoTargets and Therapy, 2026-11. Verfasst von Wencheng Chi und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer can remain clinically controlled for prolonged periods yet retain a persistent risk of acquired resistance and late recurrence. Although genetic evolution is a major determinant of treatment failure, accumulating evidence indicates that therapeutic pressure also reshapes the phenotypic states of surviving cancer cells before stable resistance becomes clinically apparent. In this structured narrative review, we examine therapy-driven cell-state plasticity in ER+/HER2− breast cancer, with particular emphasis on endocrine therapy and CDK4/6 inhibition. Estrogen deprivation, direct ER antagonism or degradation, and CDK4/6 inhibition impose distinct selective constraints and can generate different residual cell-state landscapes rather than a uniform resistant phenotype. These treatment-adapted states are sustained by interacting programs involving lineage and transcriptional reprogramming, chromatin remodeling, cell-cycle control, metabolic adaptation, and microenvironmental support. Drug-tolerant persistence may provide one route through which surviving populations remain exposed to continued selection and subsequently acquire more durable resistance, but it is not an obligatory intermediate. Likewise, persistence, dormancy, residual disease, acquired resistance, and recurrence are biologically related yet distinct phenomena, and current evidence does not support a universal linear trajectory linking them. Longitudinal tissue profiling, single-cell and multi-omic approaches, circulating tumor DNA, circulating tumor cells, and disseminated tumor cell analyses are beginning to resolve tumor evolution over time, although direct monitoring of non-genetic cell states remains limited. Prospective trials targeting emerging ESR1 mutations demonstrate that molecular evolution can already be intercepted before radiographic progression, providing a clinical precedent for earlier intervention. Future progress will require reproducible state definitions, longitudinal and lineage-resolved measurements, validated biomarkers, and prospective evidence that therapeutically intercepting an evolving state improves clinical outcomes.
Zitieren
APA
Chi, W., Ren, H., Han, X., Jiang, J., & Miao, M. (2026). Therapy-Driven Cell-State Plasticity inER-Positive/HER2-Negative Breast Cancer: Adaptive Persistence, Acquired Resistance, and Recurrence—A Structured Narrative Review. OncoTargets and Therapy, Volume 19, 1-28. https://doi.org/10.2147/ott.s661018
Vancouver
Chi W, Ren H, Han X, Jiang J, Miao M. Therapy-Driven Cell-State Plasticity inER-Positive/HER2-Negative Breast Cancer: Adaptive Persistence, Acquired Resistance, and Recurrence—A Structured Narrative Review. OncoTargets and Therapy. 2026;Volume 19:1-28. doi:10.2147/ott.s661018
BibTeX
@article{Chi2026,
author = {Chi, Wencheng and Ren, Hongxu and Han, Xiao and Jiang, Jiakang and Miao, Miao},
title = {Therapy-Driven Cell-State Plasticity inER-Positive/HER2-Negative Breast Cancer: Adaptive Persistence, Acquired Resistance, and Recurrence—A Structured Narrative Review},
journal = {OncoTargets and Therapy},
year = {2026},
volume = {Volume 19},
pages = {1--28},
doi = {10.2147/ott.s661018}
}
EUVIMED